Broker research reports for stocks which have been upgraded by brokers. Both recommendation upgrades,
as well as share price target upgrades are available for companies in Industry - Pharmaceuticals.
Broker Research reports: latest Upgrades
for Industry - Pharmaceuticals
Although the company continues to strengthen its presence through new launches, portfolio expansion, and biosimilar development, persistent pricing pressure in the U.S. generics business and adverse product mix are expected to remain key headwinds to its overall profitability.
The 2QFY26 margin performance of Dr Reddy’s was marginally weaker than our expectations (in line with street estimates; adjusted for one-offs), with the gross margin (GM) decline being sharper than our expectations (at 55%, GM logged at its lowest since the launch of gRevlimid) and largely a consequence of lower-than-expected gRevlimid sales.
Dr Reddy’s Labs (DRRD) delivered slightly better-than-expected revenue/EBITDA (3%/5% beat) in 2QFY26. Higher other income and a lower tax rate led to a 14% beat in PAT.
Q2FY26 Upbeat numbers across parameters - Sales stood at 1654 crore, reflecting a ~35% YoY growth and a growth of ~5.3% QoQ. The CDMO business saw impressive growth of 58% YoY, reaching 471 crore. Generic FDF also grew 58% YoY to 518 crore and the Generic APIs segment grew ~11% YoY to 617 crore. EBITDA stood at 403 crore with a margin of 24.4%, marking a significant improvement of 979 basis points YoY. PAT stood 193.8 crore, driven by a favourable product mix and strong operational performance....
Acutaas Chemicals registered a superlative performance in Q2FY26. Revenue, EBITDA and PAT registered strong growth of 24%,95% and 94% respectively on YoY terms. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 29%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the...
Laurus Lab (LAURUS) delivered yet another better-than-expected quarter with a 6%/18%/38% beat on revenue/EBITDA/PAT. Higher formulation sales (FDF; backed by robust ARV revenue), a superior mix in the CDMO segment, and improving operating leverage led to a strong 2QFY26 performance.
Revenue from the Indian market grew 10.8% YoY to Rs. 1,811cr, led by outperformance in focus therapies. The US market's revenue grew 18.9% YoY to Rs. 308cr, as recent launches achieved the targeted market shares. Market revenue from Brazil rose 11.2% YoY to Rs. 218cr, driven by top brands and the performance of...
Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures.
